Guardant Health, Inc.
GH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | 0.19 | -0.06 | -0.50 |
| FCF Yield | -7.33% | -11.40% | -13.92% | -2.80% |
| EV / EBITDA | -11.69 | -7.50 | -6.52 | -30.63 |
| Quality | ||||
| ROIC | -33.74% | -35.16% | -37.91% | -20.34% |
| Gross Margin | 60.79% | 59.74% | 65.23% | 67.11% |
| Cash Conversion Ratio | 0.55 | 0.68 | 0.47 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.02% | 14.71% | 16.17% | 20.35% |
| Free Cash Flow Growth | 20.41% | 10.72% | -36.22% | -79.80% |
| Safety | ||||
| Net Debt / EBITDA | -2.08 | -0.51 | -2.00 | -2.45 |
| Interest Coverage | -171.87 | -219.06 | -211.24 | -159.49 |
| Efficiency | ||||
| Inventory Turnover | 4.08 | 3.67 | 3.03 | 4.01 |
| Cash Conversion Cycle | 95.43 | 73.87 | 38.54 | 72.10 |